Kindred Biosciences Company Profile (NASDAQ:KIN)

About Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences logoKindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KIN
  • CUSIP: N/A
  • Web: www.kindredbio.com
Capitalization:
  • Market Cap: $197.65 million
  • Outstanding Shares: 27,838,000
Average Prices:
  • 50 Day Moving Avg: $7.66
  • 200 Day Moving Avg: $7.02
  • 52 Week Range: $3.90 - $9.65
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.89
  • P/E Growth: -0.14
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.07 per share
  • Price / Book: 2.20
Profitability:
  • EBIDTA: ($24,990,000.00)
  • Return on Equity: -37.00%
  • Return on Assets: -35.40%
Debt:
  • Current Ratio: 29.87%
  • Quick Ratio: 29.87%
Misc:
  • Average Volume: 234,934 shs.
  • Beta: 0.18
  • Short Ratio: 2.64
 

Frequently Asked Questions for Kindred Biosciences (NASDAQ:KIN)

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.

Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?

5 equities research analysts have issued twelve-month target prices for Kindred Biosciences' stock. Their predictions range from $7.50 to $10.50. On average, they expect Kindred Biosciences' stock price to reach $9.00 in the next year. View Analyst Ratings for Kindred Biosciences.

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 714,173 shares, a decrease of 29.0% from the July 14th total of 1,005,956 shares. Based on an average daily trading volume, of 242,575 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.8% of the company's shares are sold short.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:

  • Wendy Wee, Chief Financial Officer
  • Denise M. Bevers, Chief Operating Officer, Secretary
  • Stephen Sundlof Ph.D., Executive Vice President - Regulatory Affairs and Quality, Chief Scientific Officer
  • Herbert D. Montgomery, Independent Director
  • Raymond Townsend, Independent Director
  • Ervin Veszpremi, Independent Director

Who owns Kindred Biosciences stock?

Kindred Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (5.87%), Vanguard Group Inc. (3.20%), EcoR1 Capital LLC (1.96%), Wells Fargo & Company MN (1.42%), AJO LP (1.20%) and State Street Corp (0.92%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?

Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Prudential Financial Inc., Goldman Sachs Group Inc., Granite Investment Partners LLC and Dimensional Fund Advisors LP. Company insiders that have sold Kindred Biosciences stock in the last year include Park West Asset Management Llc and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.

Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?

Kindred Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including AJO LP, Vanguard Group Inc., State Street Corp, Northern Trust Corp, Citigroup Inc., EAM Investors LLC, TIAA CREF Investment Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario, Park West Asset Management Llc and Raymond Townsend. View Insider Buying and Selling for Kindred Biosciences.

How do I buy Kindred Biosciences stock?

Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of Kindred Biosciences stock can currently be purchased for approximately $6.75.


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kindred Biosciences (NASDAQ:KIN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (33.33% upside)

Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017AegisInitiated CoverageBuy$10.50HighView Rating Details
5/31/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/15/2017BMO Capital MarketsReiterated RatingHold$8.00N/AView Rating Details
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
11/1/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$7.50N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Kindred Biosciences (NASDAQ:KIN)
Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)
Earnings History by Quarter for Kindred Biosciences (NASDAQ KIN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.33)($0.29)ViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.30)ViewListenView Earnings Details
3/1/2017Q416($0.36)($0.29)ViewListenView Earnings Details
11/7/2016Q316($0.36)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.44)($0.36)ViewN/AView Earnings Details
8/10/2015Q2($0.42)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.40)($0.34)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.18)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS

Dividends

Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kindred Biosciences (NASDAQ:KIN)
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 51.98%
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2017Park West Asset Management LlcMajor ShareholderBuy600,000$7.50$4,500,000.00View SEC Filing  
7/3/2017Richard ChinInsiderSell13,000$8.26$107,380.00View SEC Filing  
6/22/2017Richard ChinInsiderSell13,000$7.75$100,750.00View SEC Filing  
6/8/2017Park West Asset Management LlcMajor ShareholderBuy15,311$6.65$101,818.15View SEC Filing  
5/11/2017Park West Asset Management LlcMajor ShareholderBuy155,076$6.83$1,059,169.08View SEC Filing  
3/15/2017Park West Asset Management LlcMajor ShareholderBuy400,000$6.60$2,640,000.00View SEC Filing  
3/13/2017Park West Asset Management LlcMajor ShareholderBuy4,200$6.20$26,040.00View SEC Filing  
3/9/2017Park West Asset Management LlcMajor ShareholderBuy18,066$6.08$109,841.28View SEC Filing  
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.00View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.00View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.94View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.45View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Kindred Biosciences (NASDAQ:KIN)
Latest Headlines for Kindred Biosciences (NASDAQ:KIN)
Source:
DateHeadline
americanbankingnews.com logoKindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in July
www.americanbankingnews.com - August 14 at 3:04 AM
americanbankingnews.com logoKindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 8 at 10:40 PM
americanbankingnews.com logoKindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 11:14 AM
finance.yahoo.com logoEdited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 5:40 AM
finance.yahoo.com logoKindred Biosciences Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 7:38 PM
finance.yahoo.com logoKindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting
finance.yahoo.com - August 4 at 11:59 PM
americanbankingnews.com logo Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - August 2 at 10:14 PM
americanbankingnews.com logoKindred Biosciences, Inc. (KIN) Short Interest Update
www.americanbankingnews.com - July 29 at 7:15 AM
reuters.com logoBRIEF-Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing
www.reuters.com - July 29 at 1:09 AM
finance.yahoo.com logoKindred Biosciences to Announce Second Quarter 2017 Financial Results
finance.yahoo.com - July 24 at 10:19 AM
americanbankingnews.com logoKindred Biosciences, Inc. (NASDAQ:KIN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 14 at 10:52 PM
americanbankingnews.com logoPark West Asset Management Llc Purchases 600,000 Shares of Kindred Biosciences, Inc. (KIN) Stock
www.americanbankingnews.com - July 14 at 7:59 PM
finance.yahoo.com logoKindredBio Announces Pricing of Public Offering
finance.yahoo.com - July 13 at 6:07 AM
reuters.com logoBRIEF-Kindredbio announces proposed public offering of common stock
www.reuters.com - July 12 at 1:51 AM
finance.yahoo.com logoKindredBio Announces Proposed Public Offering of Common Stock
finance.yahoo.com - July 12 at 1:51 AM
americanbankingnews.com logoKindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - July 11 at 2:28 PM
bizjournals.com logoFormer Boehringer Ingelheim manufacturing plant finds new owner
www.bizjournals.com - July 7 at 6:46 AM
americanbankingnews.com logoRichard Chin Sells 13,000 Shares of Kindred Biosciences, Inc. (KIN) Stock
www.americanbankingnews.com - July 6 at 8:06 PM
finance.yahoo.com logoWill Kindred Biosciences (KIN) Continue to Surge Higher?
finance.yahoo.com - June 30 at 11:13 PM
streetinsider.com logoKindred Biosciences (KIN) Buys Kansas Manufacturing Plant and Reports Execution of Commercial Manufacturing Agreement for Zimeta
www.streetinsider.com - June 26 at 8:03 PM
reuters.com logoBRIEF-Kindred Biosciences reports acquisition of Kansas manufacturing plant
www.reuters.com - June 26 at 8:03 PM
finance.yahoo.com logoKindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta
finance.yahoo.com - June 26 at 8:03 PM
americanbankingnews.com logoKindred Biosciences, Inc. (KIN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 19 at 10:48 PM
americanbankingnews.com logoKindred Biosciences, Inc. (KIN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 17 at 12:32 AM
americanbankingnews.com logoKindred Biosciences, Inc. (KIN) Research Coverage Started at Aegis
www.americanbankingnews.com - June 16 at 8:30 AM
finance.yahoo.com logoKindred Biosciences Added to the Russell 2000 Index
finance.yahoo.com - June 16 at 7:04 AM
americanbankingnews.com logoZacks: Analysts Expect Kindred Biosciences, Inc. (KIN) to Announce -$0.29 EPS
www.americanbankingnews.com - June 15 at 2:20 PM
americanbankingnews.com logoKindred Biosciences, Inc. (KIN) Major Shareholder Purchases $101,818.15 in Stock
www.americanbankingnews.com - June 12 at 7:34 PM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - June 2 at 3:08 PM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Rating Reiterated by FBR & Co
www.americanbankingnews.com - June 1 at 4:14 PM
finance.yahoo.com logoKindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference
finance.yahoo.com - May 30 at 10:22 AM
americanbankingnews.com logoBMO Capital Markets Reaffirms Hold Rating for Kindred Biosciences Inc (KIN)
www.americanbankingnews.com - May 29 at 1:34 PM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 27 at 7:36 PM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Short Interest Update
www.americanbankingnews.com - May 25 at 11:05 AM
finance.yahoo.com logoKindred Biosciences to Present at 7th Annual LD Micro Invitational
finance.yahoo.com - May 24 at 11:16 AM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 24 at 8:22 AM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Earns Outperform Rating from Analysts at FBR & Co
www.americanbankingnews.com - May 24 at 7:20 AM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Major Shareholder Buys $1,059,169.08 in Stock
www.americanbankingnews.com - May 15 at 10:34 PM
finance.yahoo.com logoEdited Transcript of KIN earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 6 at 6:12 PM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 9:38 PM
americanbankingnews.com logoBMO Capital Markets Reiterates Hold Rating for Kindred Biosciences Inc (KIN)
www.americanbankingnews.com - May 5 at 9:34 PM
americanbankingnews.com logoKindred Biosciences (KIN) Given Daily Media Sentiment Rating of -0.12
www.americanbankingnews.com - May 4 at 9:48 AM
reuters.com logoBRIEF-Kindred Biosciences announces Q1 loss per share $0.30
www.reuters.com - May 4 at 1:16 AM
seekingalpha.com logoKindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 4 at 1:16 AM
finance.yahoo.com logoInvestor Network: Kindred Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 8:16 PM
finance.yahoo.com logoKindred Biosciences Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 8:16 PM
finance.yahoo.com logoKindred Bio reports 1Q loss
finance.yahoo.com - May 3 at 8:16 PM
americanbankingnews.com logoKindred Biosciences (KIN) Receives Daily Coverage Optimism Score of -0.12
www.americanbankingnews.com - May 1 at 3:42 PM
finance.yahoo.com logoKindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses
finance.yahoo.com - May 1 at 1:03 PM
americanbankingnews.com logoKindred Biosciences (KIN) Given Daily News Sentiment Rating of -0.12
www.americanbankingnews.com - April 28 at 12:40 PM

Social

Chart

Kindred Biosciences (KIN) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff